IDH2 and astrocytoma (excluding glioblastoma): Previous studies have shown in a grade-for-grade comparison within the astrocytoma group, IDH-mutant tumors have significantly longer progression-free survival (PFS) and overall survival (OS) compared to their IDH-wildtype counterparts [7,8].